Skip to main content
SpringerLink
Log in

Anti-herpes viruses agents

  • Symposium on Antimicrobials—I
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Antiviral agents with demonstrated efficacy are currently available for the management of infections in children caused by the herpes viruses including herpes simples type 1 (HSV1) and type 2 (HSV2), varicella-zoster virus (VZV), and cytomegalovirus (CMV). Recently, progress has been made in the development of newer agents with enhanced activity against these viruses including resistant strains. This review focuses on the activity, clinical pharmacology, and clinical indications of antiviral agents used in the treatment of infections caused by the different herpes viruses in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Prober CG. Antiviral agents and interferons. In: Long SS, Pickering LK, Prober CG, eds.Principles and Practice or Pediatic Infectious Diseases. New York; Churchill Livingstone. 1997: 1682–1703.

    Google Scholar 

  2. Jacobson MA. Valacicolvir (BW 256U87): the L-valyl ester of acyclovir.J Med Virol 1993; (Suppl) 1: 150–153.

    Article  PubMed  Google Scholar 

  3. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.Drugs 1994; 47 (1): 153–205.

    PubMed  CAS  Google Scholar 

  4. Whitley RJ, Alford AC, Hirsch MSet al. Vidarabine versus acyclovir therapy in herpes simples encephalitis.N Engl J Med 1986; 314 (3): 144–9.

    Article  PubMed  CAS  Google Scholar 

  5. Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in imunocompromised children.J Infect Dis 1988; 157 (2): 309–13.

    PubMed  CAS  Google Scholar 

  6. Balfour HH Jr., Bean, B, Laskin OL, Ambinder RFet al. Acyclovir halts progression of herpes zoster in immunocompromised patients.N Engl J Med 1983; 308 (24): 1448–53.

    Article  PubMed  Google Scholar 

  7. Corey L, Benedetti J, Critchlowet al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy.J Antimicrob Chemother 1983 (Suppl); 79–88.

    Google Scholar 

  8. Report of the Committee on Infectious Diseases. Red Book 2000 (25th edn.)American Academy of Pediatrics, Elk Grove Village, IL 2000.

  9. Goldberg LH, Kaufman R, Kutz TOet al. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group.Arch. Dermatol 1993; 129 (5): 582–587.

    Article  PubMed  CAS  Google Scholar 

  10. Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection.Antimicrob Agents Chemother 1987 Mar; 31 (3): 361–367.

    PubMed  CAS  Google Scholar 

  11. Laskin OL, Longstreth JA, Whelton Aet al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 1982 73 (IA): 197–201.

    Article  PubMed  CAS  Google Scholar 

  12. Revankar SG, Applegate AL, Markovitz DM. Delirium associated with acyclovir treatment in a patient with renal failure.Clin Infect Dis 1995 (2): 435–436.

    Google Scholar 

  13. Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient.Arch Intern Med 2000; 160 (11): 1705–6.

    Article  PubMed  CAS  Google Scholar 

  14. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).Medicine (altimore) 1997; 76 (5): 369–380.

    Article  CAS  Google Scholar 

  15. Brown ZA, Baker DA. Acyclovir therapy during pregnancy.Obstet Gynecol 1989; 73 (3) Pt 2): 526–531.

    PubMed  CAS  Google Scholar 

  16. Laufer DS, Starr SE. Resistance to antivirals.Pediatr Clin North Am 1995 42 (3): 583–99.

    PubMed  CAS  Google Scholar 

  17. Englund JA, Zimmerman ME, Swierkosz EMet al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care centre.Ann Intern Med 1990 15; 112 (6): 416–422.

    Google Scholar 

  18. Grose C, Wiedeman J. Generic acyclovir vs. famciclovir and valacyclovir.Pediatr Infect Dis J 1997; 16 (9): 838–841.

    Article  PubMed  CAS  Google Scholar 

  19. Fan-Havard P, Nahata MC, Brady MT. Ganciclovir-a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections.J Clin Pharm Ther 1989; 14 (5): 329–340.

    PubMed  CAS  Google Scholar 

  20. Markham A, Faulds D, Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.Drugs 1994 48 (3): 455–484.

    Article  PubMed  CAS  Google Scholar 

  21. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants.Ann Intern Med 1988; 109 (10): 783–788.

    PubMed  CAS  Google Scholar 

  22. Anders HJ, Goebel FD. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome.Int J STD AIDS 1999; 10 (3): 151–159, quiz 160–161.

    Article  PubMed  CAS  Google Scholar 

  23. Faqi AS, Klug A, Merker HJ, Chahoud I. Ganciclovir induces reproductive hazards in male rates after short-term exposure.Hum exp Toxicol 1997 16 (9): 505–511.

    Article  PubMed  CAS  Google Scholar 

  24. Spector SA, Hsia K, Wolf D, Shinkai M, Smith I. Molecular detection of human cytomegalovirus and determination genotypic ganciclovir resistance in clinical specimens.Clin Infect Dis 1995; 21 Suppl 2: S170–173.

    PubMed  CAS  Google Scholar 

  25. Erice A. Resistance of human cytomegalovirus to antiviral drugs.Clin Microbiol Rev 1999; 12 (2) 286–297.

    PubMed  CAS  Google Scholar 

  26. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.Drugs 1994; 48 (2): 199–226.

    Article  PubMed  CAS  Google Scholar 

  27. MacGregor RR, Graziani AL, Weiss R, Grunwald JE, Gambertioglio JG. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.J Infect Dis 1991; 164 (4): 785–787.

    PubMed  CAS  Google Scholar 

  28. Deray G, Martinex F, Katlama Cet al. Foscarnet nephrotoxicity: mechanism incidence and prevention.An J Nephrol 1989; 9 (4): 316–321.

    CAS  Google Scholar 

  29. Plosker GL, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDSDrugs 1999; 58 (2): 325–345.

    Article  PubMed  CAS  Google Scholar 

  30. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36 (2): 127–143.

    Article  PubMed  CAS  Google Scholar 

  31. Lalezari JP, Staff RJ, Kuppermann BDet al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.Ann Intern Med 1997 15; 126 (4): 257–263.

    Google Scholar 

  32. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.J Am Acad Dermatol 1998; 39 (5 Pt 1): 741–745.

    Article  PubMed  Google Scholar 

  33. De Smet MD, Meenken CJ, van den Horn GJ. Formivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis.Ocul Immunol Inflamm 1999 Dec; 7 (3–4): 189–198.

    Article  PubMed  Google Scholar 

  34. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents.J Cell Physiol 1999; 181 (2): 251–7.

    Article  PubMed  CAS  Google Scholar 

  35. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.Drugs 1982 May; 23 (5): 329–353.

    Article  PubMed  CAS  Google Scholar 

  36. Denis J, Chouraqui P, Karpouzas I, Hoang-Xuan T, Pouliquen Y. Treatment of superficial herpes simplex keratitis with vidarabine (Vira A): multicenter study of 100 cases.J Fr Ophthalmol 1990; 13 (3): 143–150.

    CAS  Google Scholar 

  37. De Clercq E. Antivirals for the treatment of herpes virus infections.J Antimicrob Chemother 1993; 32 (Suppl A): 121–132.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Devision of Infectious, Diseases Children's Hospital of Michigan Wayne State University, School of Medicine, 3901 Beaubien Blvd, 48201, Detroit, Michigan

    Nahed M. Abdel-Haq & Basim I. Asmar

Authors
  1. Nahed M. Abdel-Haq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basim I. Asmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basim I. Asmar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abdel-Haq, N.M., Asmar, B.I. Anti-herpes viruses agents. Indian J Pediatr 68, 649–654 (2001). https://doi.org/10.1007/BF02752280

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02752280

Key words

Search

Navigation